Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
S
014950
vs
K
KOSPI 200
Over the past 12 months, Samik Pharm Co Ltd has underperformed KOSPI 200, delivering a return of -12% compared to KOSPI 200's +119% growth.
Stocks Performance
014950 vs KOSPI 200
Performance Gap
014950 vs KOSPI 200
Performance By Year
014950 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Samik Pharm Co Ltd
Glance View
Samik Pharm Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Incheon, Incheon. The company went IPO on 2025-10-27. The firm is mainly engaged in the manufacture of drugs such as circulatory machinery treatments such as Cesar Plus tablets and Eravix tablets, diabetes treatments such as Griffin tablets and Gluemser tablets, digestive machinery treatments such as Samik Pharmotidine tablets and Rebacode tablets, and antipyretic anti-inflammatory drugs such as Tamitrasemi tablets and Seklfen tablets. In addition, the Company is also engaged in the manufacturing of drugs such as treating acute or recurrent vaginal candidiasis, treating children with motion sickness, and treating alopecia. The firm sells its products in domestic and overseas markets.